Lv1
8 积分 2026-01-09 加入
KLRB1 and IL12RB1 are pretherapeutic predictors of time to relapse in patients with psoriasis treated with IL-17 blockade
1个月前
已完结
Real-life intraclass switch among IL-17 inhibitors in psoriasis: results from a single-centre, 24-week, retrospective study
1个月前
已完结
A map of molecular drug targets and therapeutics for the US FDA-approved drugs: The impact of expedited regulatory pathways and first-in-class drug approvals on drug innovation
1个月前
已完结
Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study
1个月前
已完结
Durability and long-term outcomes of biologic therapies in psoriasis
1个月前
已关闭
Association of healthy lifestyle behaviours with incident irritable bowel syndrome: a large population-based prospective cohort study
2个月前
已完结
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
2个月前
已完结
IFN-γ/IL-6 and related cytokines in chronic spontaneous urticaria: evaluation of their pathogenetic role and changes during omalizumab therapy
2个月前
已完结
Chronic Spontaneous Urticaria
2个月前
已关闭
Insights into omalizumab use in Auckland City Hospital's immunology 2023 chronic spontaneous urticaria cohort
2个月前
已关闭
皖公网安备34019202002308
